Size Of Drug Discounts In Part D Employer-Sponsored Plans At Stake In Debate Over CMS Proposal
Executive Summary
The biopharmaceutical industry is fighting a CMS proposal that would impact the size of manufacturer discounts on drugs provided in the Medicare Part D coverage gap in an emerging type of Part D coverage for retirees – employer-sponsored group waiver plans, known as EGWPs.
You may also be interested in...
PhRMA Urges Caution In Implementing Part D “Trial-Size” Prescriptions
The Pharmaceutical Research and Manufacturers of America, as well as pharmacy and PBM groups, recommend that CMS test its proposed policy to institute trial-size prescriptions before implementing it on a widespread basis to Medicare Part D.
Nursing Home Overprescribing: Pharmacist Independence Requirement Should Start As Demo, APhA Says
CMS’ proposal to reduce overprescribing in nursing homes draws cautiously favorable response from national pharmacist group, but long-term care pharmacy firm Omnicare argues the agency has not provided adequate justification for its plan.
Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds
New study updates past commission analyses and highlights the significant margin between Medicare payments for drugs and the prices paid by 340B-eligible providers.